Should I buy or sell Reneo Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" RPHM shares. View RPHM analyst ratings or view top-rated stocks .

What is Reneo Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued twelve-month price objectives for Reneo Pharmaceuticals' shares. Their RPHM share price targets range from $3.00 to $35.55. On average, they anticipate the company's stock price to reach $18.14 in the next twelve months. This suggests a possible upside of 942.4% from the stock's current price. View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts .

How have RPHM shares performed in 2024?

Reneo Pharmaceuticals' stock was trading at $1.60 at the beginning of the year. Since then, RPHM stock has increased by 8.7% and is now trading at $1.74. View the best growth stocks for 2024 here .

When is Reneo Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RPHM earnings forecast .

How were Reneo Pharmaceuticals' earnings last quarter?

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) issued its quarterly earnings data on Monday, March, 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.03.

When did Reneo Pharmaceuticals IPO?

Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

How do I buy shares of Reneo Pharmaceuticals?

Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RPHM

Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free RPHM Stock Alerts

$1.74

-0.02 (-1.14%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.70
▼
$1.75
50-Day Range: $1.60
▼
$1.77
52-Week Range: $0.98
▼
$11.30

Volume: 82,987 shs
Average Volume: 280,559 shs
Market Capitalization: $58.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.14

Get Reneo Pharmaceuticals alerts:

Reneo Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.88 Rating Score
Upside/Downside: 942.4% Upside
$18.14 Price Target
Short Interest: Bearish
13.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.85) to ($0.56) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.87 out of 5 stars

Medical Sector

811th out of 911 stocks

Pharmaceutical Preparations Industry

364th out of 411 stocks

2.9

Analyst's Opinion

Consensus Rating
Reneo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Reneo Pharmaceuticals has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
13.12% of the float of Reneo Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Reneo Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Reneo Pharmaceuticals has recently increased by 3.55%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Reneo Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reneo Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RPHM.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Reneo Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
4 people have searched for RPHM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reneo Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
90.98% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($0.85) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reneo Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reneo Pharmaceuticals is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reneo Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

RPHM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RPHM Stock News Headlines

April 14, 2024 | thestreet.com

Reneo Pharmaceuticals Inc.

March 31, 2024 | markets.businessinsider.com

Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 28, 2024 | benzinga.com

Reneo Pharmaceuticals: Q4 Earnings Insights

March 28, 2024 | investorplace.com

RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023

March 28, 2024 | finanznachrichten.de

Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

March 28, 2024 | globenewswire.com

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

February 14, 2024 | uk.finance.yahoo.com

Reneo Pharmaceuticals, Inc. (RPHM)

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 14, 2024 | uk.finance.yahoo.com

Reneo Pharmaceuticals, Inc. (RPHM)

January 30, 2024 | investing.com

Reneo Pharmaceuticals Inc (RPHM)

December 27, 2023 | msn.com

Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

December 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)

December 16, 2023 | markets.businessinsider.com

Hold Rating on Reneo Pharmaceuticals Following Lead Drug Trial Failure and Strategic Uncertainty

December 16, 2023 | msn.com

Jefferies Downgrades Reneo Pharmaceuticals (RPHM)

December 15, 2023 | finance.yahoo.com

Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study

December 15, 2023 | realmoney.thestreet.com

Reneo Pharmaceuticals just downgraded at BofA, here's why

December 15, 2023 | markets.businessinsider.com

5 Analysts Have This to Say About Reneo Pharmaceuticals

December 15, 2023 | realmoney.thestreet.com

Reneo Pharmaceuticals just downgraded at Piper Sandler, here's why

December 15, 2023 | realmoney.thestreet.com

Reneo Pharmaceuticals just downgraded at Leerink, here's why

December 14, 2023 | marketwatch.com

Reneo Pharma Hits All-Time Low on Job Cuts, Halted Mavodelpar Development

December 14, 2023 | msn.com

Reneo stock plunges 84% as company shuts down lead program

December 14, 2023 | finance.yahoo.com

Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today?

December 14, 2023 | finanznachrichten.de

Reneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

December 14, 2023 | finance.yahoo.com

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

November 16, 2023 | markets.businessinsider.com

Positive Outlook for Reneo Pharmaceuticals: Promising Clinical Trials and Strong Financial Position Underpin Buy Recommendation

November 16, 2023 | seekingalpha.com

Reneo: Mavodelpar Data Expected December Of 2023

See More Headlines

Receive RPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RPHM
CUSIP: N/A
CIK: 1637715
Web: reneopharma.com
Phone: 858-283-0280
Fax: N/A
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.14
High Stock Price Target: $35.55
Low Stock Price Target: $3.00
Potential Upside/Downside: +936.4%
Consensus Rating: Reduce
Rating Score (0-4): 1.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-77,390,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.14%
Return on Assets: -63.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.87
Quick Ratio: 5.87

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.66 per share
Price / Book: 0.66

Miscellaneous

Outstanding Shares: 33,420,000
Free Float: 27,439,000
Market Cap: $58.49 million
Optionable: Optionable
Beta: 0.24

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Michael G. Grey (Age 71)
Founder & Executive Chairman
Comp: $100k
Mr. Gregory J. Flesher (Age 54)
President, CEO & Director
Comp: $800.45k
Mr. Michael P. Cruse (Age 52)
Chief Operating Officer
Comp: $535.47k
Ms. Ashley F. Hall J.D. (Age 52)
Chief Development Officer
Comp: $661.55k
Ms. Jennifer P. Lam
Senior VP of Finance, Principal Financial & Accounting Officer
Dr. Alejandro Dorenbaum M.D. (Age 63)
Chief Medical Officer
Comp: $477.65k
Ms. Lynn Purkins Ph.D.
Senior Vice President of Global Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RPHM Stock Analysis - Frequently Asked Questions

Should I buy or sell Reneo Pharmaceuticals stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" RPHM shares.
View RPHM analyst ratings or view top-rated stocks.
What is Reneo Pharmaceuticals' stock price target for 2024?: 8 equities research analysts have issued twelve-month price objectives for Reneo Pharmaceuticals' shares. Their RPHM share price targets range from $3.00 to $35.55. On average, they anticipate the company's stock price to reach $18.14 in the next twelve months. This suggests a possible upside of 942.4% from the stock's current price.
View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts.
How have RPHM shares performed in 2024?: Reneo Pharmaceuticals' stock was trading at $1.60 at the beginning of the year. Since then, RPHM stock has increased by 8.7% and is now trading at $1.74.
View the best growth stocks for 2024 here.
When is Reneo Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RPHM earnings forecast.

How were Reneo Pharmaceuticals' earnings last quarter?: Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) issued its quarterly earnings data on Monday, March, 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.03.
When did Reneo Pharmaceuticals IPO?: Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.
How do I buy shares of Reneo Pharmaceuticals?: Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPHM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

Reneo Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)

RPHM Stock Price History

RPHM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RPHM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™